Treatment: dapsone (Disulone)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Before starting
Laboratory tests
- FBC with reticulocyte count
- G6PD assay
- AST
- ALT
- Serum creatinine with eGFR
Monitoring on treatment (and after any dose increase)
Every week during the first month (first check on day 8)
- FBC with reticulocyte count
- Methaemoglobin level
At 1 month, in addition
- AST
- ALT
- Serum creatinine with eGFR
- Serum ferritinif neededIn long-term treatment, the SmPC (RCP) asks for transferrin saturation, ferritin and liver function tests one month after the start and then periodically, to detect iron excess linked to the ferrous oxalate in the tablet and to haemolysis [2].
- Transferrin saturationif neededIn long-term treatment, the SmPC (RCP) asks for transferrin saturation, ferritin and liver function tests one month after the start and then periodically, to detect iron excess linked to the ferrous oxalate in the tablet and to haemolysis [2].
Every month, from the 2nd to the 6th month
- FBC with reticulocyte count
Then every 3 months
- FBC with reticulocyte count
- AST
- ALT
- Serum creatinine with eGFR
- Serum ferritin and transferrin saturation (periodically, long-term treatment)if neededThe ferrous oxalate in the tablet and haemolysis expose to iron overload and liver damage: transferrin saturation, ferritin and liver function tests one month after the start and then periodically [2].
- Fructosamine (diabetic patient: if HbA1c does not match plasma glucose readings)if neededOn dapsone, HbA1c may be underestimated because of haemolysis or methaemoglobinaemia; the SmPC (RCP) then advises fructosamine [2]. NABM procedure 1576, not combinable with HbA1c (1577) [6].
Do not order
- HbA1c alone to follow diabetes on dapsone: it is underestimated; in case of discordance with blood glucose readings, measure fructosamine [2].
Sources (6)
- Assurance maladie. Open Medic 2025 : nombre de consommants par substance active (ATC5), médicaments remboursés délivrés en officine de ville (fichier NB_2025_atc5). open-data-assurance-maladie.ameli.fr.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit DISULONE 100 mg/200 mg, comprimé sécable (dapsone, oxalate ferreux), rubriques 4.1 à 4.9 ; mise à jour du 29/09/2026, consulté le 12 octobre 2026.
- US Food and Drug Administration (DailyMed). Dapsone tablets USP 25 mg et 100 mg (AvKARE ; fabricant Jacobus) : prescribing information, rubriques Warnings et Precautions, version du 13 janvier 2026.
- Tillomed Laboratories. Dapsone 50mg Tablets : Summary of Product Characteristics, rubriques 4.3 et 4.4, révision du 29 août 2024 (electronic medicines compendium).
- Zorginstituut Nederland. Farmacotherapeutisch Kompas : dapson, rubriques Zwangerschap, Contra-indicaties et Waarschuwingen en voorzorgen, consulté le 29/10/2026.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0559 (méthémoglobine), 1518 (G6PD), 1109 (réticulocytes), 1576 (protéines glyquées, type fructosamine).